Literature DB >> 27082303

Efficacy of Intravitreal Injections of Triamcinolone Acetonide in a Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy.

Tzu-Lun Huang1, Yao-Tseng Wen2, Chung-Hsing Chang3, Shu-Wen Chang4, Kung-Hung Lin5, Rong-Kung Tsai6.   

Abstract

PURPOSE: To investigate effects of intravitreal injections of triamcinolone acetonide (IVI-TA) at different times in a rodent model of nonarteritic anterior ischemic optic neuropathy (rAION).
METHODS: After inducing ischemic optic neuropathy, the rats received either IVI-TA (0.32 mg/2 μL) at 1 day (1d-TA), 1 week (7d-TA), 2 weeks (14d-TA), or PBS. The density of retinal ganglion cells (RGCs) was calculated using retrograde Fluorogold labeling. Electrophysiological visual function was assessed by flash visual evoked potentials (FVEPs). Apoptosis assays of the retinal sections and immunohistochemistry of ED1 staining of the optic nerves were performed.
RESULTS: Four weeks postinfarct, the 1d- and 7d-TA groups had significantly rescued RGCs in the central (2160 ± 250 mm(2), P = 0.004; 2050 ± 660, P = 0.008, respectively) and midperipheral retinas (1240 ± 130; 1250 ± 220, respectively, both P = 0.004) compared with those of the PBS-treated rats. Flash visual evoked potentials demonstrated improvements in P1 amplitude (μV) in the 1d- and 7d-TA groups (both P < 0.05). Assays of TUNEL showed a decrease in the number of apoptotic cells in the RGC layers of 1d- and 7d-TA-treated retinas compared with the PBS-treated group (both P = 0.004). Cells ED1-positive were significantly decreased in the optic nerve (ON) of the 1d- and 7d-TA groups compared with the PBS group (P = 0.004 and 0.02, respectively).
CONCLUSIONS: Within 1 week postinfarct of rAION, IVI-TA had neuroprotective effects on RGC survival with an increase in the electrophysiological amplitude of VEPs and a decrease in microglial infiltration in the ONs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27082303     DOI: 10.1167/iovs.15-19023

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Use of Intravitreal Dexamethasone in a Case of Anterior Ischemic Optic Neuropathy.

Authors:  Raffaele Nuzzi; Francesca Monteu
Journal:  Case Rep Ophthalmol       Date:  2017-08-31

2.  A rodent model of anterior ischemic optic neuropathy (AION) based on laser photoactivation of verteporfin.

Authors:  Jing-Yu Min; Yanan Lv; Lei Mao; Yuan-Yuan Gong; Qing Gu; Fang Wei
Journal:  BMC Ophthalmol       Date:  2018-11-22       Impact factor: 2.209

3.  Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy: A PRISMA-compliant meta-analysis.

Authors:  Jun Chen; Jie Zhu; Li Chen; Chen Hu; Yi Du
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

4.  Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION).

Authors:  Yan Guo; Zara Mehrabian; Mary A Johnson; David S Albers; Cadmus C Rich; Rudolf A Baumgartner; Steven L Bernstein
Journal:  Transl Vis Sci Technol       Date:  2019-12-20       Impact factor: 3.283

5.  Haematococcus pluvialis-Derived Astaxanthin Is a Potential Neuroprotective Agent against Optic Nerve Ischemia.

Authors:  Wei-Ning Lin; Kishan Kapupara; Yao-Tseng Wen; Yi-Hsun Chen; I-Hong Pan; Rong-Kung Tsai
Journal:  Mar Drugs       Date:  2020-01-28       Impact factor: 5.118

6.  Biomarkers of lesion severity in a rodent model of nonarteritic anterior ischemic optic neuropathy (rNAION).

Authors:  Yan Guo; Zara Mehrabian; Mary A Johnson; Neil R Miller; Amanda D Henderson; John Hamlyn; Steven L Bernstein
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

7.  Transcriptomic Analysis Reveals That Granulocyte Colony-Stimulating Factor Trigger a Novel Signaling Pathway (TAF9-P53-TRIAP1-CASP3) to Protect Retinal Ganglion Cells after Ischemic Optic Neuropathy.

Authors:  Rong-Kung Tsai; Keh-Liang Lin; Chin-Te Huang; Yao-Tseng Wen
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.